Skip to main content

decipheriNg Oncogenic SIgnalling patterns to break CAncer drug Resistance

Project description

Molecular insight into drug resistance mechanisms in breast cancer

Breast cancer ranks as one of the most prevalent forms of cancer in women today. Despite advances in targeted therapies, nearly 25 % of patients do not respond to treatment, or they develop drug resistance. The scope of the EU-funded NOSCAR project is to investigate the mechanisms of resistance to therapy. Scientists will focus on the oncogenic Ras/Erk and PI3K/Akt/mTOR signalling pathways known for their role in cell survival, proliferation, motility and metabolism. They will assess how these pathways are rewired in the presence of clinically relevant breast cancer mutations or following drug treatment. The project's results have the potential to identify novel targets for treating breast cancer in the future.

Call for proposal

H2020-MSCA-IF-2019
See other projects for this call

Coordinator

UNIVERSITAET BERN
Address
Hochschulstrasse 6
3012 Bern
Switzerland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 304 724,16